TAVALISSE (fostamatinib)
Chronic Immune Thrombocytopenia (ITP)
Key Facts
About Rigel Pharmaceuticals
Rigel Pharmaceuticals has successfully transitioned from a discovery-focused research organization to a fully integrated commercial biotech with two marketed products: TAVALISSE® for chronic immune thrombocytopenia (ITP) and REZLIDHIA® for relapsed/refractory AML with an IDH1 mutation. The company's strategy centers on expanding the labels of its commercial assets, advancing its clinical pipeline in hematology-oncology and immunology, and pursuing strategic collaborations. With a seasoned leadership team and a focus on dysregulated signaling pathways, Rigel aims to build a sustainable portfolio in niche hematologic and oncologic markets.
View full company profileAbout Rigel Pharmaceuticals
Rigel Pharmaceuticals has successfully transitioned from a discovery-focused research organization to a fully integrated commercial biotech with two marketed products: TAVALISSE® for chronic immune thrombocytopenia (ITP) and REZLIDHIA® for relapsed/refractory AML with an IDH1 mutation. The company's strategy centers on expanding the labels of its commercial assets, advancing its clinical pipeline in hematology-oncology and immunology, and pursuing strategic collaborations. With a seasoned leadership team and a focus on dysregulated signaling pathways, Rigel aims to build a sustainable portfolio in niche hematologic and oncologic markets.
View full company profileTherapeutic Areas
Other Chronic Immune Thrombocytopenia (ITP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Fostamatinib (TAVALISSE) | Nippon Shinyaku | Approved |
| Fostamatinib (TAK-079 / MND-379) | Mochida Pharmaceutical | Launched |
| Doptelet (avatrombopag) | Swedish Orphan Biovitrum | Marketed / Phase 4 |